Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Sagent Pharmaceuticals Bupivacaine hydrochloride injection.
Subscribe to our email newsletter
Bupivacaine hydrochloride is used for inducing local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
Bupivacaine Hydrochloride Injection is available in six single-dose and two multi-dose latex-free vials.
Bupivacaine also features the company’s PreventIV MeasuresSM packaging and labeling design to reduce medication errors.
Sagent has developed Bupivacaine in collaboration with Strides Arcolab who will be responsible to develop and supply injectable products that Sagent will market in the US.